IL272895B2 - Therapeutic metal complexes and ligands and methods of making and using same - Google Patents

Therapeutic metal complexes and ligands and methods of making and using same

Info

Publication number
IL272895B2
IL272895B2 IL272895A IL27289520A IL272895B2 IL 272895 B2 IL272895 B2 IL 272895B2 IL 272895 A IL272895 A IL 272895A IL 27289520 A IL27289520 A IL 27289520A IL 272895 B2 IL272895 B2 IL 272895B2
Authority
IL
Israel
Prior art keywords
compound
formula
disease
subject
use according
Prior art date
Application number
IL272895A
Other languages
English (en)
Hebrew (he)
Other versions
IL272895A (en
IL272895B1 (en
Inventor
Beaudry Chris
Hurst James
Beckman Joseph
Sirois John
Original Assignee
Univ Oregon State
Beaudry Chris
Hurst James
Beckman Joseph
Sirois John
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon State, Beaudry Chris, Hurst James, Beckman Joseph, Sirois John filed Critical Univ Oregon State
Publication of IL272895A publication Critical patent/IL272895A/en
Publication of IL272895B1 publication Critical patent/IL272895B1/en
Publication of IL272895B2 publication Critical patent/IL272895B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/08—Copper compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL272895A 2017-09-01 2018-08-31 Therapeutic metal complexes and ligands and methods of making and using same IL272895B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762553714P 2017-09-01 2017-09-01
PCT/US2018/049163 WO2019046761A1 (en) 2017-09-01 2018-08-31 THERAPEUTIC METAL COMPLEXES AND LIGANDS, METHODS OF MAKING AND USING SAME

Publications (3)

Publication Number Publication Date
IL272895A IL272895A (en) 2020-04-30
IL272895B1 IL272895B1 (en) 2025-02-01
IL272895B2 true IL272895B2 (en) 2025-06-01

Family

ID=63684510

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272895A IL272895B2 (en) 2017-09-01 2018-08-31 Therapeutic metal complexes and ligands and methods of making and using same

Country Status (8)

Country Link
US (2) US11596651B2 (enExample)
EP (1) EP3676271A1 (enExample)
JP (2) JP2020532538A (enExample)
CN (1) CN111278835A (enExample)
AU (1) AU2018325283B2 (enExample)
CA (1) CA3074258A1 (enExample)
IL (1) IL272895B2 (enExample)
WO (1) WO2019046761A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020532538A (ja) * 2017-09-01 2020-11-12 オレゴン ステイト ユニバーシティー 治療用金属錯体およびリガンドならびにその作成および使用の方法
BR112022001301A2 (pt) * 2019-07-25 2022-04-12 Als Therapy Development Inst Cuptsm para o tratamento de distúrbios neurodegenerativos
JP2023544965A (ja) 2020-08-26 2023-10-26 エイエルエス・セラピー・デヴェロップメント・インスティテュート 神経変性障害の治療のための銅錯体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061306A1 (en) * 2006-11-20 2008-05-29 The University Of Melbourne Metal delivery agents and therapeutic uses of the same
WO2015070177A2 (en) * 2013-11-11 2015-05-14 Collaborative Medicinal Development, Llc Metal complexes and methods of treatment
WO2017070752A1 (en) * 2015-10-29 2017-05-04 The University Of Queensland Imaging agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7403524A (en) 1959-09-15 1974-05-27 Pharmaceutical compsn. - contg. alpha-dithiosemicarbazone active against trichomonas vaginalis
US4107210A (en) 1976-09-07 1978-08-15 The Dow Chemical Company Synthesis of alpha-diketones
CA2166676C (en) * 1995-01-09 2007-05-01 Yasuhisa Fujibayashi Diagnostic agent for hypoxia or mitochondrial dysfunction comprising radioactive copper complex of dithiosemicarbazone derivative or diamine diol schiff base derivative
GB0617299D0 (en) * 2006-09-01 2006-10-11 Isis Innovation Compounds for imaging and therapy
AU2009326867B2 (en) * 2008-12-12 2015-10-29 The University Of Melbourne Process for the preparation of asymmetrical bis(thiosemicarbazones)
WO2017214546A1 (en) * 2016-06-10 2017-12-14 University Of Louisville Research Foundation, Inc. Compounds, related compositions, catalysts, electrochemical cells, fuel cells, their preparation and their uses
WO2018204564A1 (en) * 2017-05-04 2018-11-08 University Of Louisville Research Foundation, Inc. Thiosemicarbazone derivatives as anti-cancer agents
JP2020532538A (ja) * 2017-09-01 2020-11-12 オレゴン ステイト ユニバーシティー 治療用金属錯体およびリガンドならびにその作成および使用の方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061306A1 (en) * 2006-11-20 2008-05-29 The University Of Melbourne Metal delivery agents and therapeutic uses of the same
WO2015070177A2 (en) * 2013-11-11 2015-05-14 Collaborative Medicinal Development, Llc Metal complexes and methods of treatment
WO2017070752A1 (en) * 2015-10-29 2017-05-04 The University Of Queensland Imaging agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DEARLING J L J ET AL:, REDOX-ACTIVE METAL COMPLEXES FOR IMAGING HYPOXIC TISSUES: STRUCTURE-ACTIVITY RELATIONSHIPS IN COPPER(!I) BIS(THIOSEMICARBAZONE) COMPLEXES, 21 November 1998 (1998-11-21) *
EUGENE A. COATS ET AL:, COMPARATIVE ANALYSIS OF THE CYTOTOXICITY OF SUBSTITUTED [PHENYLGLYOXAL BIS(4-METHYL-3-THIOSEMICARBAZONE)]COPPER(LL) CHELATES. 2. PARABOLIC CORRELATIONS AND THEIR IMPLICATIONS FOR SELECTIVE TOXICITY, 1 August 1978 (1978-08-01) *
EUGENE A. COATS ET AL:, COMPARATIVE ANALYSIS OF THE CYTOTOXICITY OF SUBSTITUTED [PHENYLGLYOXAL BIS(4-METHYL-3-THIOSEMICARBAZONE]COPPER(LI) CHELATES, 1 January 1976 (1976-01-01) *
LARRY E. WARREN ET AL:, THE MASS SPECTRA OF SOME COPPER(!I) COMPLEXES RELATED TO ANTI-CARCINOGENS, 1 January 2012 (2012-01-01) *
ZDENA DURACKOVA ET AL:, THIOHYDRAZONE COPPER(LL) COMPLEXES. THE RELATIONSHIP BETWEEN REDOX PROPERTIES AND SUPEROXIDE DISMUTASE MIMETIC ACTIVITY, 1 February 1999 (1999-02-01) *

Also Published As

Publication number Publication date
IL272895A (en) 2020-04-30
AU2018325283B2 (en) 2023-11-16
US12403159B2 (en) 2025-09-02
US20230172977A1 (en) 2023-06-08
JP2024001064A (ja) 2024-01-09
WO2019046761A1 (en) 2019-03-07
CA3074258A1 (en) 2019-03-07
JP2020532538A (ja) 2020-11-12
US11596651B2 (en) 2023-03-07
AU2018325283A1 (en) 2020-03-12
EP3676271A1 (en) 2020-07-08
US20200188430A1 (en) 2020-06-18
IL272895B1 (en) 2025-02-01
CN111278835A (zh) 2020-06-12

Similar Documents

Publication Publication Date Title
JP7219497B2 (ja) Ｐｓｍａ結合剤及びその使用
AU2002218262B2 (en) Treatment of gastrointestinal stromal tumors
KR102008635B1 (ko) 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
Naqvi et al. Ciprofloxacin: from infection therapy to molecular imaging
IL272895B2 (en) Therapeutic metal complexes and ligands and methods of making and using same
KR102634247B1 (ko) 다발성 골수종을 치료하기 위한 약물 병용물
JP2010529088A5 (enExample)
ES2759312T3 (es) Compuestos de aminocarbonilcarbamato
JP6987840B2 (ja) Ｉｄｏ１酵素イメージングのための放射性リガンド
JP2019527740A5 (enExample)
Shah et al. Radiosynthesis and biological evaluation of 99m TcN-sitafloxacin dithiocarbamate as a potential radiotracer for Staphylococcus aureus infection
JP2020532538A5 (enExample)
CN1367690A (zh) 使用五氟苯磺酰胺的综合疗法
CN102153542A (zh) 抗电离辐射损伤防护药物
JP6656484B2 (ja) 放射性抗腫瘍剤
JP6085810B2 (ja) 放射性医薬及び医薬キット
Hausner et al. Synthesis of 5-and 6-substituted 2-(4-dimethylaminophenyl)-1, 3-benzoxazoles and their in vitro and in vivo evaluation as imaging agents for amyloid plaque
WO2011133893A2 (en) Cyanide antidotes
AU2004273911B2 (en) Mechanism-based targeted pancreatic beta cell imaging and therapy
TWI856060B (zh) 口服二氧戊環核苷酸與抗pd1或抗pdl1單株抗體併用治療肝癌之方法
JP5322651B2 (ja) シンチグラフィー法
JPH05505624A (ja) ラジオグラフィ造影剤として有用なヘキサデンテートリガンド類
RU2236848C1 (ru) Средство, уменьшающее токсичность противоопухолевых препаратов
JP6494400B2 (ja) 放射性抗腫瘍剤、及び、抗腫瘍用キット
Pryma et al. A Mighty Oak Forest from a Single, Well-Planted Acorn (perspective on “Radiolabeled Adrenergic Neuron-Blocking Agents: Adrenomedullary Imaging with [131I] Iodobenzylguanidine” J Nucl Med. 1980; 21: 349–353)